Next Phase Newsletter

A private equity firm headquartered in China provides venture capital and growth capital to growth-stage companies across various industries, including life sciences, Internet, consumables, software, and high technology sectors (i.e. drones). The firm is interested in all types of life science companies except drug development. The allocation size will vary, but the firm has the capability to allocate up to $40 million per company, depending on the opportunity. The investment is typically in form of equity, but convertible loan will be considered as well. The firm has an emphasis on technologies and products, and it is currently seeking new investment opportunities globally. Companies with a China angle will be a big plus.

The firm is currently seeking to invest in medical device, diagnostics, biotech R&D services and healthcare IT sectors. The firm is very opportunistic in terms of subsectors and indications. Currently the firm will not invest in companies targeting drug development. The firm will consider companies at all stages of development, from pre-clinical stage all through to commercial stage; however, the firm prefers companies in the business proven stage, where the product is on the market and may already have customer feedback.

The firm primarily invests in growth-stage private companies. The firm does not have specific requirements for companies’ management team or revenues. The firm will take a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established venture capital firm based in the USA invests globally in medically related early-stage companies. Initial size of investment ranges from $250 – 500K. While the firm is focused on USA-based companies, the firm is open to considering companies across the globe.

The firm invests in medtech and digital health companies. While the founder has decades of experience as an oculofacial plastic surgeon, the firm is generally opportunistic and will consider any promising technologies that address unmet medical need. The firm has looked at AI companies, digital health/software companies implementable in medical practices, etc. In terms of stage of development, the firm is open to investing as early as pre-prototype, given that the company has properly researched the idea behind their technology.

The firm has no specific company or management team requirements, and is open to acting as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A cross-border life science investment firm that focuses on investments in therapeutics, medical devices, diagnostics, and life science tools recently closed a new fund and currently manages over $2B. In addition to investing in Chinese and American companies, the firm is actively involved in supporting their portfolio companies through cross-border partnerships. The firm generally makes investments ranging from $5-30 MM USD.

For pharmaceuticals, the firm looks at assets ranging from Ph I to marketed with a preference towards post-Phase IIb products, but is open to promising, earlier stage opportunities with strong clinical data. For medical device products, the firm looks at a wide variety of products with a preference for technologies that are soon to be market ready. Sector interests include but are not limited to cardiovascular, surgical, ENT, orthopedics, wound care, robotics, and others. For diagnostics, the firm invests in a broad range of technology including POCT, IVD, and molecular diagnostics but also targets non-conventional and invasive diagnostics (such as IVUS/OCT, breath based, GI, etc…). The firm is also interested in revenue generating companies working in the animal health space.

The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A publicly NASDAQ-traded diagnostics company with operations in USA and China specializes in pre-cancer and cancer screening based on biophysical properties. The firm is looking to partner or acquire a majority share in early stage companies in the diagnostics space. While the firm is looking to be the majority stakeholder in these companies, the firm is most interested in continuing a partnership/joint venture with these startups, as opposed to a full acquisition. The firm is willing to partner globally.

The firm is interested in diagnostics companies only. Within diagnostics, the firm is interested in two types of partnerships.

First, the firm is seeking oncology diagnostics that use genetic or biomarker identification of specific cancer types that can be paired with their technology, meshing the specific genetic/biomarker for these cancers with the biophysical anomalies they detect.

Additionally, the firm is also looking to partner with companies in the oncology space that are seeking to expand to China and can take advantage of the firm’s existing infrastructure. For these partnerships, the firm is interested in all forms of diagnostics in all indications.

The firm is looking to acquire at least a 51% stake in the companies with which they are partnering, but is open to any structures that are advantageous for all parties. As a partner, the firm has facilities in place for any additional research or clinical tests needed to help companies reach commercialization in the United States, as well as the ability to help with distribution, especially in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in USA and Western Europe has multi-billion in assets under management and its mandate is to create companies with Seed and Series A funding (typically $50-100M), but it can also deploy smaller tickets into academic institutions for direct research funding. The firm seeks to make investments around the globe with a focus on creating and building companies located within the US and Europe.

The firm builds transformative life science companies by following the science, working with the best people, and investing for long term value creation. The firm is currently looking for companies in the Therapeutics space. The firm is most interested in companies developing novel biologics, however companies developing small molecules or biologic substitutes are also considered for investment. The firm is willing to invest in companies with a product in any phase of development, but it has a strong preference for discovery/preclinical assets.

The firm requires board seats in its portfolio companies. The firm also prefers to lead (or co-lead) any investment syndicates and looks to optimize the asset with additional resources beyond the typical venture investment mandate. The firm’s seasoned team of venture partners and entrepreneurs in-residence can also assume interim C-level positions, allowing recruiting flexibility as the company grows.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm manages the investments in innovation for a large integrated delivery network health system with over 15 hospitals and 35,000 providers and employees.  The firm is responsible for sourcing external innovation investments outside of the hospital system, and seeks early-stage co-investment opportunities led by quality lead venture firms, coupled with a strong emphasis on co-development opportunities with early-stage companies where the firm’s expertise in clinical, population health, health insurance services, and digital security can be most value-adding. The firm is open to global opportunities.

Currently, the firm is most interested in investments in digital health, HCIT, and process transformation opportunities, and will consider medical devices (predominantly of the wearables, monitoring types). The firm does not consider therapeutics companies at this time.

The firm is opportunistic, but examples of previous engagements have been in technologies targeting care administration/operations, cancer, cardiology, neuroscience and ALS, and even health-focused cybersecurity.  As the firm heavily weights the ability to be an active co-development partner, it is open to the earliest stage digital health technologies, but companies who have yet to close a Seed round will be considered too early.

The firm does not have specific company or management team requirements.  The Investment Office intends to leverage lead VC due diligence in its co-investment assessments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established international investment banking and financial services firm with global offices is exclusively backed by a family office venture fund with over 20 years of investing in life sciences. The firm’s check sizes greatly vary depending on the deal and stage of development. The firm generally participates in rounds beyond seed stage. The firm actively seeks global opportunities.

The firm is most interested in therapeutics and diagnostics companies, but is also open to reviewing opportunities in medical devices, digital health, and research tools/equipment. Within therapeutics, the firm is excited about NCEs. In terms of disease area of indication, the firm has no particular preference and is opportunistic. The firm will expect to see a working prototype and a clear commercialization pathway established.

The firm places high importance on the management team and the story behind the company. While the firm is open to working with first-time or relatively inexperienced CEOs/management teams, BEP would like to see that the management team has relevant prior experience that will enable the company to successfully grow. The firm seeks to be a hands-on investor and can leverage their suite of services to help their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.